Pretreatment ¹⁸F-FDG PET/CT Imaging Predicts the KRAS/NRAS/BRAF Gene Mutational Status in Colorectal Cancer

Table 2

Distribution of genetic mutations in the primary CRC tumors (n = 85).

Gene mutational status	Cases (%)
Mutated group (mutation in KRAS, NRAS, or BRAF)	46 (54.12%)
Mutated KRAS only	40 (47.06%)
Mutated NRAS only	3 (3.53%)
Mutated BRAF only	2 (2.35%)
Mutated KRAS and BRAF simultaneous	1 (1.18%)
Wild-type group (no mutation)	39 (45.88%)